Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in multiple rodent models of nicotine dependence.

Xi ZX, Muldoon P, Wang XF, Bi GH, Damaj MI, Lichtman AH, Pertwee RG, Gardner EL.

Br J Pharmacol. 2019 Aug 27. doi: 10.1111/bph.14844. [Epub ahead of print]

PMID:
31454413
2.

Disruption of an enhancer associated with addictive behaviour within the cannabinoid receptor-1 gene suggests a possible role in alcohol intake, cannabinoid response and anxiety-related behaviour.

Hay EA, McEwan A, Wilson D, Barrett P, D'Agostino G, Pertwee RG, MacKenzie A.

Psychoneuroendocrinology. 2019 Aug 13;109:104407. doi: 10.1016/j.psyneuen.2019.104407. [Epub ahead of print]

3.

Identification of the First Synthetic Allosteric Modulator of the CB2 Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief.

Gado F, Di Cesare Mannelli L, Lucarini E, Bertini S, Cappelli E, Digiacomo M, Stevenson LA, Macchia M, Tuccinardi T, Ghelardini C, Pertwee RG, Manera C.

J Med Chem. 2019 Jan 10;62(1):276-287. doi: 10.1021/acs.jmedchem.8b00368. Epub 2018 Jul 23.

PMID:
29990428
4.

Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats.

Pertwee RG, Rock EM, Guenther K, Limebeer CL, Stevenson LA, Haj C, Smoum R, Parker LA, Mechoulam R.

Br J Pharmacol. 2018 Jan;175(1):100-112. doi: 10.1111/bph.14073. Epub 2017 Dec 5.

5.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview.

Alexander SP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2017 Dec;174 Suppl 1:S1-S16. doi: 10.1111/bph.13882.

6.

Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG.

Biol Psychiatry. 2018 Nov 15;84(10):722-733. doi: 10.1016/j.biopsych.2017.06.032. Epub 2017 Jul 8.

7.

The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Cairns EA, Szczesniak AM, Straiker AJ, Kulkarni PM, Pertwee RG, Thakur GA, Baldridge WH, Kelly MEM.

J Ocul Pharmacol Ther. 2017 Oct;33(8):582-590. doi: 10.1089/jop.2017.0037. Epub 2017 Jul 18.

8.

Big conductance calcium-activated potassium channel openers control spasticity without sedation.

Baker D, Pryce G, Visintin C, Sisay S, Bondarenko AI, Vanessa Ho WS, Jackson SJ, Williams TE, Al-Izki S, Sevastou I, Okuyama M, Graier WF, Stevenson LA, Tanner C, Ross R, Pertwee RG, Henstridge CM, Irving AJ, Schulman J, Powell K, Baker MD, Giovannoni G, Selwood DL.

Br J Pharmacol. 2017 Aug;174(16):2662-2681. doi: 10.1111/bph.13889. Epub 2017 Jul 7.

9.

Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers.

Zanato C, Pelagalli A, Marwick KF, Piras M, Dall'Angelo S, Spinaci A, Pertwee RG, Wyllie DJ, Hardingham GE, Zanda M.

Org Biomol Chem. 2017 Mar 1;15(9):2086-2096. doi: 10.1039/c6ob02796b.

10.

Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.

Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG, Stevenson LA, Pertwee RG, Kenakin TP, Denovan-Wright EM, Thakur GA.

ACS Chem Neurosci. 2017 Jun 21;8(6):1188-1203. doi: 10.1021/acschemneuro.6b00310. Epub 2017 Feb 7.

PMID:
28103441
11.

The Cyclic AMP Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells.

Marini P, Cascio MG, Pertwee RG.

Methods Mol Biol. 2016;1412:85-93. doi: 10.1007/978-1-4939-3539-0_9.

PMID:
27245894
12.

The Displacement Binding Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells.

Cascio MG, Marini P, Pertwee RG.

Methods Mol Biol. 2016;1412:57-63. doi: 10.1007/978-1-4939-3539-0_6.

PMID:
27245891
13.

Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.

Laprairie RB, Kulkarni AR, Kulkarni PM, Hurst DP, Lynch D, Reggio PH, Janero DR, Pertwee RG, Stevenson LA, Kelly ME, Denovan-Wright EM, Thakur GA.

ACS Chem Neurosci. 2016 Jun 15;7(6):776-98. doi: 10.1021/acschemneuro.6b00041. Epub 2016 Apr 25.

14.

Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence.

Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S.

Neurosci Biobehav Rev. 2016 May;64:359-81. doi: 10.1016/j.neubiorev.2016.03.010. Epub 2016 Mar 14. Review.

PMID:
26987641
15.

The Concise Guide to PHARMACOLOGY 2015/16: Overview.

Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, Catterall WA, Cidlowski JA, Davenport AP, Fabbro D, Fan G, McGrath JC, Spedding M, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2015 Dec;172(24):5729-43. doi: 10.1111/bph.13347.

16.

Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).

Kulkarni PM, Kulkarni AR, Korde A, Tichkule RB, Laprairie RB, Denovan-Wright EM, Zhou H, Janero DR, Zvonok N, Makriyannis A, Cascio MG, Pertwee RG, Thakur GA.

J Med Chem. 2016 Jan 14;59(1):44-60. doi: 10.1021/acs.jmedchem.5b01303. Epub 2015 Nov 28.

17.

Endocannabinoids and Their Pharmacological Actions.

Pertwee RG.

Handb Exp Pharmacol. 2015;231:1-37. doi: 10.1007/978-3-319-20825-1_1. Review.

PMID:
26408156
18.

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Mounsey RB, Mustafa S, Robinson L, Ross RA, Riedel G, Pertwee RG, Teismann P.

Exp Neurol. 2015 Nov;273:36-44. doi: 10.1016/j.expneurol.2015.07.024. Epub 2015 Aug 2.

19.

CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.

Smoum R, Baraghithy S, Chourasia M, Breuer A, Mussai N, Attar-Namdar M, Kogan NM, Raphael B, Bolognini D, Cascio MG, Marini P, Pertwee RG, Shurki A, Mechoulam R, Bab I.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8774-9. doi: 10.1073/pnas.1503395112. Epub 2015 Jun 29.

20.

The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.

Cascio MG, Zamberletti E, Marini P, Parolaro D, Pertwee RG.

Br J Pharmacol. 2015 Mar;172(5):1305-18. doi: 10.1111/bph.13000.

21.

Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459.

Goonawardena AV, Plano A, Robinson L, Ross R, Greig I, Pertwee RG, Hampson RE, Platt B, Riedel G.

Behav Pharmacol. 2015 Apr;26(3):289-303. doi: 10.1097/FBP.0000000000000108.

22.

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

McPartland JM, Duncan M, Di Marzo V, Pertwee RG.

Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944. Review.

23.

Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.

Brizzi A, Aiello F, Marini P, Cascio MG, Corelli F, Brizzi V, De Petrocellis L, Ligresti A, Luongo L, Lamponi S, Maione S, Pertwee RG, Di Marzo V.

Bioorg Med Chem. 2014 Sep 1;22(17):4770-83. doi: 10.1016/j.bmc.2014.07.006. Epub 2014 Jul 12.

PMID:
25065940
24.

In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.

Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, Thakur GA, Tichkule R, Poklis J, Ross RA, Pertwee RG, Lichtman AH.

Behav Pharmacol. 2014 Apr;25(2):182-5. doi: 10.1097/FBP.0000000000000027.

25.

Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol.

Romano B, Borrelli F, Pagano E, Cascio MG, Pertwee RG, Izzo AA.

Phytomedicine. 2014 Apr 15;21(5):631-9. doi: 10.1016/j.phymed.2013.11.006. Epub 2013 Dec 25.

PMID:
24373545
26.

Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.

Pertwee RG.

Proc Nutr Soc. 2014 Feb;73(1):96-105. doi: 10.1017/S0029665113003649. Epub 2013 Oct 18. Review.

PMID:
24135210
27.

Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.

Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C.

Neuropharmacology. 2013 Dec;75:155-63. doi: 10.1016/j.neuropharm.2013.07.024. Epub 2013 Aug 4.

PMID:
23924692
28.

Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.

Hill TD, Cascio MG, Romano B, Duncan M, Pertwee RG, Williams CM, Whalley BJ, Hill AJ.

Br J Pharmacol. 2013 Oct;170(3):679-92. doi: 10.1111/bph.12321.

29.

Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.

Marini P, Cascio MG, King A, Pertwee RG, Ross RA.

Br J Pharmacol. 2013 Jun;169(4):887-99. doi: 10.1111/bph.12191.

30.

The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.

Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M, Pertwee R, Coppola D, Vassallo L, Orlando P, Di Marzo V, Izzo A.

Br J Pharmacol. 2013 May;169(1):213-29. doi: 10.1111/bph.12120.

31.

Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation.

Pertwee RG.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):20781-2. doi: 10.1073/pnas.1218529110. Epub 2012 Nov 30. No abstract available.

32.

CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.

Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, McAllister S, Strange PG, Stephens GJ, Pertwee RG, Ross RA.

Mol Pharmacol. 2013 Feb;83(2):322-38. doi: 10.1124/mol.112.080879. Epub 2012 Nov 15.

33.

Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation.

Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, Stott CG, Javid FA, Parker LA, Pertwee RG.

Br J Pharmacol. 2013 Mar;168(6):1456-70. doi: 10.1111/bph.12043.

34.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

35.

Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators.

Brown I, Cascio MG, Rotondo D, Pertwee RG, Heys SD, Wahle KW.

Prog Lipid Res. 2013 Jan;52(1):80-109. doi: 10.1016/j.plipres.2012.10.001. Epub 2012 Oct 26. Review.

PMID:
23103355
36.

Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.

Pasquini S, De Rosa M, Ligresti A, Mugnaini C, Brizzi A, Caradonna NP, Cascio MG, Bolognini D, Pertwee RG, Di Marzo V, Corelli F.

Eur J Med Chem. 2012 Dec;58:30-43. doi: 10.1016/j.ejmech.2012.09.035. Epub 2012 Oct 3.

PMID:
23085772
37.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9.

38.

Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach.

Mugnaini C, Nocerino S, Pedani V, Pasquini S, Tafi A, De Chiaro M, Bellucci L, Valoti M, Guida F, Luongo L, Dragoni S, Ligresti A, Rosenberg A, Bolognini D, Cascio MG, Pertwee RG, Moaddel R, Maione S, Di Marzo V, Corelli F.

ChemMedChem. 2012 May;7(5):920-34. doi: 10.1002/cmdc.201100573. Epub 2012 Mar 2.

39.

Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.

Brizzi A, Cascio MG, Frosini M, Ligresti A, Aiello F, Biotti I, Brizzi V, Pertwee RG, Corelli F, Di Marzo V.

J Med Chem. 2011 Dec 22;54(24):8278-88. doi: 10.1021/jm200529h. Epub 2011 Nov 16.

PMID:
22044209
40.

Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.

Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA.

J Biol Chem. 2012 Jan 2;287(1):91-104. doi: 10.1074/jbc.M111.296020. Epub 2011 Oct 25.

41.

Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines.

Brown I, Wahle KW, Cascio MG, Smoum-Jaouni R, Mechoulam R, Pertwee RG, Heys SD.

Prostaglandins Leukot Essent Fatty Acids. 2011 Dec;85(6):305-10. doi: 10.1016/j.plefa.2011.09.007. Epub 2011 Oct 12.

PMID:
21995886
42.

Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.

Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA.

Br J Pharmacol. 2012 Apr;165(8):2620-34. doi: 10.1111/j.1476-5381.2011.01621.x.

43.

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.

J Neurosci Res. 2011 Sep;89(9):1509-18. doi: 10.1002/jnr.22682. Epub 2011 Jun 14.

PMID:
21674569
44.

AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.

Bolognini D, Cascio MG, Parolaro D, Pertwee RG.

Br J Pharmacol. 2012 Apr;165(8):2561-74. doi: 10.1111/j.1476-5381.2011.01503.x.

45.

Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors.

Bátkai S, Mukhopadhyay P, Horváth B, Rajesh M, Gao RY, Mahadevan A, Amere M, Battista N, Lichtman AH, Gauson LA, Maccarrone M, Pertwee RG, Pacher P.

Br J Pharmacol. 2012 Apr;165(8):2450-61. doi: 10.1111/j.1476-5381.2011.01410.x.

46.

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.

García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J.

Br J Pharmacol. 2011 Aug;163(7):1495-506. doi: 10.1111/j.1476-5381.2011.01278.x.

47.

Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.

Rock EM, Goodwin JM, Limebeer CL, Breuer A, Pertwee RG, Mechoulam R, Parker LA.

Psychopharmacology (Berl). 2011 Jun;215(3):505-12. doi: 10.1007/s00213-010-2157-4. Epub 2011 Jan 18.

PMID:
21243485
48.

Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Wiley JL, Breivogel CS, Mahadevan A, Pertwee RG, Cascio MG, Bolognini D, Huffman JW, Walentiny DM, Vann RE, Razdan RK, Martin BR.

Eur J Pharmacol. 2011 Jan 25;651(1-3):96-105. doi: 10.1016/j.ejphar.2010.10.085. Epub 2010 Nov 27.

49.

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA.

Pharmacol Rev. 2010 Dec;62(4):588-631. doi: 10.1124/pr.110.003004. Review.

50.

Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines.

Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, Pertwee RG, Heys SD.

Carcinogenesis. 2010 Sep;31(9):1584-91. doi: 10.1093/carcin/bgq151. Epub 2010 Jul 25.

Supplemental Content

Loading ...
Support Center